Latest Breaking News On - Orphan disease designation - Page 6 : comparemela.com

Mazindol Demonstrates Safety Profile in Narcolepsy Treatment

Mazindol for narcolepsy demonstrated a very low risk for drug-drug interactions and positive pharmacological differentiation.

George apostolDrug administrationPharmaceutics ltdEuropean medicines agency for mazindolOrphan disease designationEuropean medicines agency

NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer

NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.

Marianne lambertsonKaizen bioscienceAlex zwyerKeith harrison dewedoffExchange commissionCode biotherapeutics incKellogg collegeDrug administrationPharmaceutics ltdNortheastern universityEuropean medicines agencyAdvisor for danforth advisorsCeptur therapeutics incVillanova universityInvestments wealth instituteInterim chief financial officer

NLS Pharmaceutics AG: NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer

ZÜRICH, SWITZERLAND / ACCESSWIRE / May 8, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and

Alex zwyerKeith harrison dewedoffMarianne lambertsonKaizen bioscienceKellogg collegePharmaceutics ltdNortheastern universityCeptur therapeutics incVillanova universityDrug administrationCode biotherapeutics incAdvisor for danforth advisorsInvestments wealth instituteEuropean medicines agencyExchange commissionInterim chief financial officer

FDA Greenlights Phase 3 Trials of Quilience for Narcolepsy

NLS Pharmaceutics received FDA authorization to proceed with the phase 3 AMAZE program for Quilience (mazindol ER) for narcolepsy treatment.

George apostolAlex zwyerDrug administrationEuropean medicines agencyPharmaceutics ltdOrphan disease designationEuropean medicines

NLS Pharmaceutics Receives Green Light from the U S FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy

NLS Pharmaceutics Receives Green Light from the U S FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesGeorge apostolMarianne lambertsonAlex zwyerEuropean medicines agencyDrug administrationAmerican academy of sleep medicineExchange commissionPharmaceutics ltdResearch societyWall streetChief executive officerAmerican academySleep medicineSleep research societyChief medical